• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $EPIX

    ESSA Pharma Inc.

    Subscribe to $EPIX
    $EPIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

    IPO Year:

    Exchange: NASDAQ

    Website: essapharma.com

    Peers

    $LIFE
    $EVOK
    $MEIP

    Recent Analyst Ratings for ESSA Pharma Inc.

    DatePrice TargetRatingAnalyst
    11/4/2024Buy → Hold
    Jefferies
    11/4/2024Outperform → Perform
    Oppenheimer
    11/4/2024$15.00 → $2.00Overweight → Neutral
    Piper Sandler
    6/26/2023$17.00Outperform
    Oppenheimer
    8/17/2021$36.00 → $22.00Outperform
    Oppenheimer
    See more ratings

    ESSA Pharma Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow

      5/8/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

      3/6/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal first quarter ended December 31, 2024. "Following our decision to terminate the clinical development of masofaniten, we have been evaluating and reviewing strategic options with a focus on maximizing shareholder valu

      2/11/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

      Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. "We recently made the difficult decision to terminate the clinical development of m

      12/17/24 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

      Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens  A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy data showed the single-agent enzalutamide control arm performing better than historical controls and similar to the combination of masofaniten and enzalutamide and therefore, unlikely to achieve the primary endpoint of the study  Additional clinical studies with masofaniten including the combination study with abiraterone acetate and apalutamide as well as the remaining investigator sponsored trials will also

      10/31/24 8:57:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

      Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 88% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. After 15.2 months of follow up, median time to PSA progression and radiographic progression free survival have not yet been reached. SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 13, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pha

      9/13/24 5:19:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 11, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the Company will be presenting at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 9:10 a.m. ET in New York, NY. David R. Parkinson, President and Chief Executive Officer, Peter Virsik, Chief Operating Officer and Executive Vice President, and David S. Wood, Chief Financial Officer, will participate in a fireside chat. A live webcast of the fireside chat can be accessed in the Investors/Events

      9/11/24 4:05:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

      On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations well beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 5, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the

      8/5/24 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma to Present at the JonesHealthcare Seaside Summit

      SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 8, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will present at the JonesHealthcare Seaside Summit on Monday, July 15, 2024 at 11:00 a.m. PT. David R. Parkinson, President and Chief Executive Officer, will host the presentation and will also participate in a panel discussion titled "Innovations and Challenges in Prostate Cancer" at 9:00 a.m. PT. A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website

      7/8/24 4:05:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma to Present at the Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 30, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 p.m. ET in New York. David. R. Parkinson, President, and Chief Executive Officer and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings. A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. F

      5/30/24 8:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ESSA Pharma Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Parkinson David Ross bought $21,213 worth of shares (9,223 units at $2.30), increasing direct ownership by 16% to 65,675 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      12/18/23 9:57:03 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berger Franklin M bought $133,274 worth of shares (23,259 units at $5.73), increasing direct ownership by 3% to 784,404 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      11/22/23 6:22:47 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berger Franklin M bought $419,661 worth of shares (76,471 units at $5.49), increasing direct ownership by 11% to 760,875 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      11/16/23 5:45:43 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ESSA Pharma Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Biotech Growth N V sold $12,018,409 worth of shares (7,879,583 units at $1.53), closing all direct ownership in the company (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      11/5/24 12:06:18 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Virsik Peter sold $4,185 worth of shares (694 units at $6.03), decreasing direct ownership by 8% to 7,776 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      10/7/24 3:00:52 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Virsik Peter sold $4,164 worth of shares (694 units at $6.00), decreasing direct ownership by 8% to 8,470 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      9/9/24 2:03:33 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Virsik Peter sold $12,554 worth of shares (2,082 units at $6.03), decreasing direct ownership by 19% to 9,164 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      9/3/24 6:57:35 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virsik Peter sold $4,823 worth of shares (694 units at $6.95), decreasing direct ownership by 6% to 11,246 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      5/6/24 5:17:29 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Glickman Richard M exercised 3,750 shares at a strike of $4.90, increasing direct ownership by 9% to 43,240 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      4/25/24 10:35:14 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Virsik Peter sold $5,510 worth of shares (694 units at $7.94), decreasing direct ownership by 5% to 11,940 units (SEC Form 4)

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      4/5/24 6:16:13 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Zweifach Sanford S

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      3/28/24 12:41:34 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Thorell Marella

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      3/28/24 12:40:22 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Sollis Gary

      4 - ESSA Pharma Inc. (0001633932) (Issuer)

      3/28/24 12:39:13 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ESSA Pharma Inc. Leadership Updates

    Live Leadership Updates

    See more
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at seven and re-elected to the board of directors, by ordinary resolution passed by ballot

      3/6/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berg

      3/7/24 8:13:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, USA and VANCOUVER, CANADA, March 7, 2024  /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 6, 2024 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at ten and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin

      3/7/24 8:13:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Appoints Lauren Merendino to its Board of Directors

      SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors. Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios. "Lauren's cross-functional expertise in guiding products through all stages of commercial development adds a valuable perspective that complements the sk

      6/6/23 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors

      Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and

      11/17/22 4:15:00 PM ET
      $EPIX
      $PBYI
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Appoints Philip Kantoff to its Board of Directors

      SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors. Dr. Kantoff brings invaluable insight and experience to ESSA as a renowned medical oncologist and leader in the clinical development of new prostate cancer treatments. "Phil's breadth and quality of accomplishments are unmatched, and we are honored to welcome him to ESSA's Board of Directors," stated Richard M. Glickman, L.L.D. (Hon), Chairman of ESSA's

      9/13/22 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

      SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 9, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on March 9, 2022 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") resolved to set the number of directors of the Company at eight and re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Fr

      3/9/22 11:34:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders

      HOUSTON and VANCOUVER, BC, Feb. 25, 2021 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX) (TSX-V: EPI), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on February 25, 2021 (the "Meeting"). At the Meeting, the shareholders of the Company (the "Shareholders") re-elected to the board of directors, by ordinary resolution passed by ballot vote, David R. Parkinson, Richard M. Glickman, Gary Sollis, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, Sandy Zweifach,

      2/25/21 6:33:00 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ESSA Pharma Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 7:32:27 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 4:04:37 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ESSA Pharma Inc.

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      11/14/24 6:56:05 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by ESSA Pharma Inc.

      SC 13D - ESSA Pharma Inc. (0001633932) (Subject)

      11/8/24 4:56:15 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ESSA Pharma Inc.

      SC 13G - ESSA Pharma Inc. (0001633932) (Subject)

      11/7/24 12:50:43 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ESSA Pharma Inc. (Amendment)

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      2/14/24 4:06:37 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ESSA Pharma Inc.

      SC 13G - ESSA Pharma Inc. (0001633932) (Subject)

      2/14/24 7:05:46 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ESSA Pharma Inc. (Amendment)

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      2/13/24 6:04:49 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ESSA Pharma Inc.

      SC 13G - ESSA Pharma Inc. (0001633932) (Subject)

      2/8/24 11:29:15 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ESSA Pharma Inc. (Amendment)

      SC 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      1/23/24 4:09:22 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ESSA Pharma Inc. Financials

    Live finance-specific insights

    See more
    • ESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, had been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal second quarter ended March 31, 2025. "We continue to rigorously evaluate strategic options with a focus on maximizing shareholder value," said David Parkinson, MD, President and CEO of ESSA. "We have taken productive steps tow

      5/8/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

      Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today reported financial results for the fiscal first quarter ended December 31, 2024. "Following our decision to terminate the clinical development of masofaniten, we have been evaluating and reviewing strategic options with a focus on maximizing shareholder valu

      2/11/25 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

      Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical trials and preclinical and other development programs, has been focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fourth quarter and fiscal year ended September 30, 2024. "We recently made the difficult decision to terminate the clinical development of m

      12/17/24 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

      On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase 1b monotherapy results expected to be reported in the second half of 2024 Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in the first quarter of 2025, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations well beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 5, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the

      8/5/24 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

      Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /C

      5/14/24 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

      Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation antiandrogens, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 dose expansion underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting completion of enrollment in 1Q25, with preliminary data expected in mid-2025 Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 14, 2024 /P

      5/14/24 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

      Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients achieving PSA90, 69% of patients achieving PSA90 in less than 90 days, and 63% of patients achieving PSA <0.2ng/mL Phase 2 masofaniten plus enzalutamide combination dose expansion study ongoing Cash runway sufficient to fund operations beyond 2025 SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer,

      2/13/24 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

      Phase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy data reported at Prostate Cancer Foundation 2023 Scientific Retreat and ESMO 2023 Head-to-head Phase 2 dose expansion underway evaluating masofaniten (EPI-7386)/enzalutamide combination versus enzalutamide monotherapy in patients with mCRPC SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financ

      12/12/23 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023

      Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023 Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing n

      8/8/23 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023

      Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment expected to begin 2H2023 Continue to enroll patients into the fourth cohort of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide); Phase 1 completion expected in 3Q2023 followed by initiation of the randomized Phase 2 part of the study Phase 1b EPI-7386 monotherapy expansion study in mCRPC patients ongoing SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 9, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceu

      5/9/23 7:00:00 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ESSA Pharma Inc. SEC Filings

    See more
    • ESSA Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ESSA Pharma Inc. (0001633932) (Filer)

      5/8/25 7:04:05 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by ESSA Pharma Inc.

      10-Q - ESSA Pharma Inc. (0001633932) (Filer)

      5/8/25 7:00:30 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13D filed by ESSA Pharma Inc.

      SCHEDULE 13D - ESSA Pharma Inc. (0001633932) (Subject)

      4/24/25 8:56:37 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13D filed by ESSA Pharma Inc.

      SCHEDULE 13D - ESSA Pharma Inc. (0001633932) (Subject)

      4/9/25 9:00:44 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ESSA Pharma Inc. (0001633932) (Filer)

      3/6/25 7:02:16 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.

      SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      2/14/25 4:06:25 PM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.

      SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      2/14/25 10:26:22 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.

      SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      2/14/25 9:49:47 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.

      SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)

      2/14/25 9:00:04 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ESSA Pharma Inc. (0001633932) (Filer)

      2/11/25 7:02:06 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    ESSA Pharma Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ESSA Pharma downgraded by Jefferies

      Jefferies downgraded ESSA Pharma from Buy to Hold

      11/4/24 8:34:37 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma downgraded by Oppenheimer

      Oppenheimer downgraded ESSA Pharma from Outperform to Perform

      11/4/24 7:26:24 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ESSA Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded ESSA Pharma from Overweight to Neutral and set a new price target of $2.00 from $15.00 previously

      11/4/24 7:26:03 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on ESSA Pharma with a new price target

      Oppenheimer resumed coverage of ESSA Pharma with a rating of Outperform and set a new price target of $17.00

      6/26/23 7:24:46 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer reiterated coverage on ESSA Pharma with a new price target

      Oppenheimer reiterated coverage of ESSA Pharma with a rating of Outperform and set a new price target of $22.00 from $36.00 previously

      8/17/21 7:19:42 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on ESSA Pharma with a new price target

      Piper Sandler initiated coverage of ESSA Pharma with a rating of Overweight and set a new price target of $50.00

      3/10/21 8:10:55 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on ESSA Pharma with a new price target

      Piper Sandler initiated coverage of ESSA Pharma with a rating of Overweight and set a new price target of $50.00

      3/4/21 5:51:10 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright reiterated coverage on ESSA Pharma with a new price target

      HC Wainwright reiterated coverage of ESSA Pharma with a rating of Buy and set a new price target of $32.00 from $36.00 previously

      3/3/21 8:12:26 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on ESSA Pharma with a new price target

      HC Wainwright & Co. reiterated coverage of ESSA Pharma with a rating of Buy and set a new price target of $32.00 from $36.00 previously

      2/25/21 9:15:34 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bloom Burton resumed coverage on ESSA Pharma

      Bloom Burton resumed coverage of ESSA Pharma with a rating of Buy

      2/13/21 7:52:51 AM ET
      $EPIX
      Biotechnology: Pharmaceutical Preparations
      Health Care